Current Research Studies
A Randomized, Open Label, Multi-Center, Phase 3 Efficacy Study of Sub-Q Abatacept (Orencia) in Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (LIMIT-JIA)
LIMIT JIA
What is the goal of the study?
The study objective is to evaluate the effectiveness of a 24-week course of treatment with a T-cell co-stimulation inhibitor (abatacept (Orencia)) plus usual care versus usual care to prevent polyarthritis (5 or more joints), uveitis, or treatment with other systemic medication(s) for JIA (e.g one or more of the following: glucocorticoids, DMARD or biologic) medication within 18 months of randomization in children with recent-onset limited JIA.
Who can participate in the study?
Please contact the study team listed below to learn more.